Unicycive Therapeutics, Inc. has reported positive results from pivotal clinical trial of Oxylanthanum Carbonate (OLC), a NCE molecule with potential treatment for hyperphosphatemia in chronic kidney disease patients which has several benefits for various patients in this chronic disease. The company is expected to file the New Drug Application for OLC by mid-2024 with potential approval by mid-2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4949 USD | +3.10% |
|
+8.29% | -42.96% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.96% | 18.61M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. Reports Positive Results from Pivotal Clinical Trial of Oxylanthanum Carbonate